Symbolbild · KI-generiert
Biocure Technology Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.
Company description as published by the issuer via Canadian Securities Exchange.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Biocure Technology Inc. | CURE.X | CSE | 792.272 USD |
| Genix Pharmaceuticals Corporation | GENX | TSXV | 654.673 USD |
| Entheon Biomedical Corp. | ENBI.X | CSE | 592.777 USD |
| Waverley Pharma Inc. | WAVE | TSXV | 577.425 USD |
| Imaging Dynamics Company Ltd. | IDL | TSXV | 552.540 USD |
| EGF Theramed Health Corp. | TMED.X | CSE | 523.518 USD |
| Lifeist Wellness Inc. | LFST | TSXV | 1 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.